Bristol Myers Squibb & Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating ...

The stock's fall snapped a two-day winning streak.

Bristol-Myers Squibb Company (NYSE: BMY) is one of the best cheap stocks under $50 to buy now. In a report released on July ...

Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and ...

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

The reduced rate will still be almost 10 times the average monthly out-of-pocket costs paid by commercially insured patients.

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

Bristol Myers Squibb (BMY) stock slips as its anemia drug Reblozyl misses primary goal in a Phase 3 trial for myelofibrosis, ...

Bristol Myers on Friday said the Phase 3 study of Reblozyl with concomitant janus-kinase-inhibitor therapy didn't meet its primary endpoint of red-blood-cell transfusion independence in adults with ...

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...

Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and ...

The companies’ new effort would bypass traditional middlemen to cut the drug’s monthly cost from a list price of around $606 ...